Hepion Pharmaceuticals Employee Directory
Biotechnology ResearchNew Jersey, United States2-10 Employees
Hepion Pharmaceuticals, Inc. (OTCQB:HEPA) is pioneering early cancer detection with novel liquid biopsy diagnostics, on a path toward integrating diagnostics and therapeutics in a closed loop theranostics model. The company is developing first-in-class liquid biopsy tests for hepatocellular carcinoma (HCC) in high-risk patients, with potential applications across other solid tumors. Hepion holds global commercialization rights to two genomic-based liquid biopsy tests, each demonstrating unprecedented sensitivity and specificity in detecting liver cancer in high-risk cirrhotic patients in clinical trials. The company’s Methylated Septin9 (mSEPT9) is a validated biomarker for HCC detection and surveillance, backed by strong clinical evidence, established IP, and a prospective clinical development plan. It has the unique ability to delineate between very early (Barcelona Clinic Liver Cancer [BCLC] stage A1) and early-stage HCC (BCLC stages A2, A3, and A4) – a key differentiator from other diagnostic tests. Its other asset, a circulating tumor RNA (ctRNA) platform that detects HCC-specific mutant RNA variants in blood, represents a next-generation approach to liquid biopsy. The ctRNA asset is in-licensed from Cirna Diagnostics, a spinout company out of the Baruch S. Blumberg Institute (BSBI). Liver cancer is the fastest growing and fifth deadliest cancer in the United States and the third deadliest cancer globally. Early HCC is asymptomatic, making screening high-risk patients critical, yet the current standard of care misses up to 75% of cases. The global liquid biopsy market is currently valued at $10 billion and growing, and in the U.S. alone is projected to reach nearly $9 billion by 2035. Hepion's flexible business models, strong IP position, and public company structure create multiple pathways to value creation for partners ready to make a real impact in oncology.
1-888-653-2347 
support@leadiq.com 
